Avalo Therapeutics, Inc. (AVTX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$25.3M
Cash & Equivalents
$17.7M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$1,010M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-16 8-K Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) - EX-99.2 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for AVTX.

SEC EDGAR Filings

All SEC filings for Avalo Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.